Key result
Apixaban linked to ~27% lower recurrent VTE risk vs. warfarin in obese patients.
Why the study?
This study was conducted to evaluate the risk of recurrent VTE and major bleeding among VTE patients who initiated apixaban versus warfarin, stratified by obesity.
Does apixaban reduce the risk of recurrent venous thromboembolism and major bleeding compared to warfarin in VTE patients with obesity and morbid obesity?
Cohort (n=155,119)
Yes
Does apixaban reduce the risk of recurrent venous thromboembolism and major bleeding compared to warfarin in VTE patients with obesity and morbid obesity?
This large real-world claims analysis demonstrates that apixaban is associated with lower risks of recurrent VTE and major bleeding compared to warfarin in both obese and morbidly obese VTE patients, supporting DOAC use in high-BMI populations where prior clinical data were limited.
Answers are grounded in this paper and cite their sources.
Apixaban may be favored over warfarin for lower recurrent VTE in obese patients; extends observational data but leaves open need for RCTs before practice change.
This study integrated 5 United States healthcare claims databases to evaluate the risk of recurrent venous thromboembolism (VTE) and major bleeding (MB) among VTE patients who initiated apixaban vs. warfarin, stratified by obesity. Obese and morbidly obese patients were identified based on diagnosis codes. Stabilized inverse probability treatment weighting (IPTW) was conducted to balance observed patient characteristics between treatment cohorts. An interaction analysis was conducted to evaluate treatment effects of apixaban vs. warfarin according to obesity status. Cox proportional hazard models were used to evaluate the risk of recurrent VTE and MB among IPTW weighted obese and morbidly obese patients. A total of 112,024 non-obese patients and 43,095 obese patients were identified, of whom 19,751 were morbidly obese. When stratified by obesity status post-IPTW, no significant interactions were observed for effects of apixaban vs. warfarin on recurrent VTE or MB (interaction p > 0.10). Among IPTW obese and morbidly obese patients, apixaban was associated with a significantly lower risk of recurrent VTE (obese: 0.73 [0.64–0.84]; morbidly obese: 0.65 [0.53–0.80]) and MB (obese: 0.73 [0.62–0.85]; morbidly obese: 0.68 [0.54–0.86]) as compared with warfarin. In this large sample of obese and morbidly obese VTE patients, apixaban had a significantly lower risk of recurrent VTE and MB vs. warfarin.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2021) conducted a cohort in Venous thromboembolism (VTE) with obesity and morbid obesity (n=155,119). Apixaban vs. Warfarin was evaluated on Recurrent venous thromboembolism (VTE) in obese patients (HR 0.73, 95% CI 0.64-0.84). Apixaban was associated with a lower risk of recurrent VTE vs. warfarin in obese and morbidly obese patients.
Synapse has enriched 10 related papers. Consider them for comparative context: